XML 20 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1

Note 6 - Inventory

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Inventory Disclosure [Text Block]

6.

Inventory

Inventory consists of the following (in thousands):

		June 30, 2018				December 31, 2017
Raw materials		$	8,175			$	2,754
Work in process			9,520				4,166
Finished goods			9,502				3,188
Total inventory		$	27,197			$	10,108

As of

June 30, 2018,

total inventory included

$8.5

million and

$18.7

million related to SUSTOL and CINVANTI, respectively. As of

December 31, 2017,

total inventory included

$7.1

million and

$3.0

million related to SUSTOL and CINVANTI, respectively.

Prior to FDA approval,

$1.4

million of costs to manufacture CINVANTI were recorded to research and development expense in prior periods. By

March 31, 2018,

all CINVANTI units that were manufactured prior to FDA approval had been sold. We began capitalizing raw materials, labor and overhead related to the manufacturing of CINVANTI following FDA approval.

X

- References

No definition available.

+ Details

Name:	us-gaap_DisclosureTextBlockAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-URI http://asc.fasb.org/topic&trid=2126998

+ Details

Name:	us-gaap_InventoryDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration